.jetcityimage/iStock Content through Getty Images Morgan Stanley has actually picked Eli Lilly (NYSE: LLY) as its own leading biopharma pick for 2025 and also rated one more nine titles in the room as overweight. The financial investment bank pointed out in a details that it continues to believe “diabesity is set to become.